Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$487.00 | Pmlq | Nqxxdxfpxy |
Eli Lilly Earnings: Robust Growth Lifted by Broad Portfolio Strength, Especially Mounjaro
Eli Lilly reported strong third-quarter results that were largely in line with our net expectations, and we are holding firm to our Lilly fair value estimate. While the firm remains very well positioned for growth with cardiometabolic drug Mounjaro, we believe the market is overly optimistic on the outlook for the company.